유한양행
000100KOSPI의약품 제조업57.4 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
Yuhan is a company engaged in the manufacturing and sales of pharmaceuticals, chemicals, and daily necessities, with key products such as Lexapro, Antipurin, and DuoWell. In 2024, the company achieved a 5.7% revenue growth to 21.87 trillion won, despite challenges like geopolitical tensions and economic downturns. R&D efforts are highlighted by Lexapro's global commercialization and ongoing pipeline development, while operating profit and net income increased by 90.2% and 235.9% year-over-year, respectively.
Number of Employees
2,153people
Average Salary
100.0M KRW
Score Calculation Basis
Detailed Financial Score
2.8x industry avg (risky)
2.9x industry avg (risky)
2.0x industry avg (excellent)
Half of industry avg (excellent)
Avg ▲8.5% (2-year basis)
Avg ▲43.4% (2-year basis)
Avg ROE 5.8% (improving, 3yr)
Detailed News Sentiment
- Positive블랙록, 유한양행 지분 5% 확보…추가 기술수출 가능성에 선투자
블랙록의 유한양행 지분 확보로 렉라자 로열티 수입 증가 기대, 주가 상승 가능성 높아짐.
- Positive유한양행 100주년 기념 웹툰 조회수 50만 돌파
유한양행의 웹툰 'NEW 일한'이 창립 100주년 기념으로 카카오페이지에서 큰 성공을 거두며 조회수 50만을 돌파했습니다.
- NeutralVIP동물의료센터, 비뇨기 질환 최적 치료 전략 공개…'VCC' 도약 ...
VIP동물의료센터의 새로운 치료 전략 콘퍼런스 개최로 관련 산업 내 긍정적 관심 증가.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -12.84% (falling)
Volume flat
Detailed Disclosure
- Neutral주식등의대량보유상황보고서(약식)2026-06-08
- Neutral기업설명회(IR)개최(안내공시)2026-06-05
- Neutral기업설명회(IR)개최(안내공시)2026-06-05
- Neutral기업지배구조보고서공시2026-06-01
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01
